Pure Global AI
NCT06378346Recruiting

GU-01: Glycyrrhizin in Prostate Cancer

GU-01: Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Trial
University of Illinois at ChicagoPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Prostate Cancer
Drug/Device/Intervention
Glycyrrhizin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Illinois at Chicago
Location
Chicago, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Mar 01, 2026
Enrollment
60 participants
Primary outcome

Number of participants that have a change in prostate-specific antigen (PSA) before GLY administration,Number of participants that have a change in prostate-specific antigen (PSA) after GLY administration and prior to radical prostatectomy

Summary

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with
 previously untreated prostate cancer (PCa) who are candidates for surgery (radical
 prostatectomy)

ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06378346
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06378346 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Illinois at Chicago and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.